HUP9903916A2 - Foszfinsavamidok és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Foszfinsavamidok és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP9903916A2
HUP9903916A2 HU9903916A HUP9903916A HUP9903916A2 HU P9903916 A2 HUP9903916 A2 HU P9903916A2 HU 9903916 A HU9903916 A HU 9903916A HU P9903916 A HUP9903916 A HU P9903916A HU P9903916 A2 HUP9903916 A2 HU P9903916A2
Authority
HU
Hungary
Prior art keywords
alkyl
aryl
alkoxy
thioalkyl
heterocyclic
Prior art date
Application number
HU9903916A
Other languages
English (en)
Inventor
Biswanath De
Kelly Lynn Mcdow-Dunham
Stanislav Pikul
Yetunde Olabisi Taiwo
Original Assignee
The Procter And Gamble Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter And Gamble Co. filed Critical The Procter And Gamble Co.
Publication of HUP9903916A2 publication Critical patent/HUP9903916A2/hu
Publication of HUP9903916A3 publication Critical patent/HUP9903916A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/36—Amides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgyát (I) általános képletű vegyületek -ahol R1 hidrogénatom, alkil-, alkinil-alkil-, alkenil-alkil-, aralkil-,heterociklikus-alkil-, alkoxi-alkil-, aril-alkoxi-alkil- vagy alkil-tioalkil-csoport: R2 hidrogénatom, alkil-, alkinil-, alkenil-, aril-alkil-, heterociklikus alkil-, heteroalkil- (köztük alkoxi-alkil-,aril-alkoxi-alkil- vagy alkil-tioalkil-, alkil-amino-alkil-, aril-tioalkil-, aril-alkil-tioalkil-), hetero-ciklikus-heteroalkil-, amino-acil-alkil-, acil-amino-alkil-, alkoxi-karbonil-alkil-, aciloxi-alkil-csoport: R1 és R2 együtt alkilénláncot vagy heteroalkilén-láncotképeznek: R3 alkil-, cikloalkil-, ciklo-heteroalkil-, karbociklikusvagy heterociklikus aril-, heteroalkil-csoport (hidroxi-alkil-,alkoxi-alkil- vagy amino-alkil-csoport); vagy R3 és R2 együttalkilénláncot vagy heteroalkilén-láncot is képezhet; R4 alkil-,alkoxi-, aril-alkil-, cikloalkil-, karbociklikus vagy heterociklikusarilcsoport - optikai izomereik, diasztereomereik, enantiomereik,gyógyszerészetileg elfogadható sóik vagy biológiailag hidrolizálhatóalkoxi-amidjaik, észter-aciloxi-amidjaik vagy imidjeik és ezekettartalmazó, metalloproteáz aktivitással kapcsolatos betegségekkezelésére szolgáló gyógyszerkészítmények képezik. Ó
HU9903916A 1996-08-28 1997-08-22 Phosphinic acid amides and pharmaceutical compositions containing the same HUP9903916A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2476596P 1996-08-28 1996-08-28
PCT/US1997/014556 WO1998008853A1 (en) 1996-08-28 1997-08-22 Phosphinic acid amides as matrix metalloprotease inhibitors

Publications (2)

Publication Number Publication Date
HUP9903916A2 true HUP9903916A2 (hu) 2001-05-28
HUP9903916A3 HUP9903916A3 (en) 2001-06-28

Family

ID=21822291

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903916A HUP9903916A3 (en) 1996-08-28 1997-08-22 Phosphinic acid amides and pharmaceutical compositions containing the same

Country Status (27)

Country Link
US (1) US5830915A (hu)
EP (1) EP0925303B1 (hu)
JP (1) JP3539736B2 (hu)
KR (1) KR20000035925A (hu)
CN (1) CN1228780A (hu)
AR (1) AR009357A1 (hu)
AT (1) ATE226590T1 (hu)
AU (1) AU732653B2 (hu)
BR (1) BR9713182A (hu)
CA (1) CA2264254C (hu)
CO (1) CO4900033A1 (hu)
CZ (1) CZ63699A3 (hu)
DE (1) DE69716619T2 (hu)
DK (1) DK0925303T3 (hu)
HU (1) HUP9903916A3 (hu)
ID (1) ID18145A (hu)
IL (1) IL128668A (hu)
NO (1) NO990857L (hu)
NZ (1) NZ334258A (hu)
PE (1) PE107698A1 (hu)
PL (1) PL331854A1 (hu)
RU (1) RU2170232C2 (hu)
SK (1) SK25499A3 (hu)
TR (1) TR199900399T2 (hu)
TW (1) TW518338B (hu)
WO (1) WO1998008853A1 (hu)
ZA (1) ZA977700B (hu)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206874A1 (en) * 1996-11-21 2003-11-06 The Proctor & Gamble Company Promoting whole body health
WO1999006340A2 (en) 1997-07-31 1999-02-11 The Procter & Gamble Company Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
US6846478B1 (en) 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
DE19850072A1 (de) * 1998-10-30 2000-05-04 Bayer Ag Phosphinat-Peptidanaloga zur Behandlung von fibrotischen Erkrankungen
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
PT1144369E (pt) * 1999-01-27 2004-11-30 Wyeth Corp Acidos hidroxamicos de arilsulfonamidas acetilenicas e de amidas de acido fosfinico acetilenicas inibidores de tace
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
AR035313A1 (es) * 1999-01-27 2004-05-12 Wyeth Corp Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos.
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
CN1178915C (zh) 1999-01-27 2004-12-08 惠氏控股有限公司 含有炔基的异羟肟酸衍生物、其制备及其作为基质金属蛋白酶抑制剂/TNF-α转变酶抑制剂的用途
EP1165501A1 (en) 1999-03-03 2002-01-02 The Procter & Gamble Company Alkenyl- and alkynyl-containing metalloprotease inhibitors
US6297337B1 (en) 1999-05-19 2001-10-02 Pmd Holdings Corp. Bioadhesive polymer compositions
US6312474B1 (en) 1999-09-15 2001-11-06 Bio-Vascular, Inc. Resorbable implant materials
US8283135B2 (en) 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
CA2415065C (en) * 2000-06-30 2009-09-15 The Procter & Gamble Company Oral compositions comprising host-response modulating agent
EP1294383B1 (en) * 2000-06-30 2008-07-16 The Procter & Gamble Company Oral compositions comprising antimicrobial agents for the prevention of systemic diseases
JP2004504326A (ja) * 2000-07-18 2004-02-12 レオ・ファーマ・アクティーゼルスカブ マトリックスメタロプロテイナーゼ阻害剤
FR2814950B1 (fr) * 2000-10-05 2003-08-08 Oreal Utilisation d'au moins un extrait d'au moins un vegetal de la famille des ericaceae, dans des compositions destinees a traiter les signes cutanes du vieillissement
US6693099B2 (en) * 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
BR0213736A (pt) 2001-11-01 2004-10-19 Wyeth Corp ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace
PE20030701A1 (es) * 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
JP2005514461A (ja) 2002-01-18 2005-05-19 レオ・ファーマ・アクティーゼルスカブ Ｍｍｐ阻害剤
WO2005021489A2 (en) 2002-12-23 2005-03-10 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7144588B2 (en) 2003-01-17 2006-12-05 Synovis Life Technologies, Inc. Method of preventing surgical adhesions
EP1449538A1 (en) * 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation
WO2008111371A1 (ja) * 2007-03-09 2008-09-18 National University Corporation Nagoya University ホスホロアミド化合物及びその製造方法、配位子、錯体、触媒、及び光学活性アルコールの製造方法
TW201141536A (en) 2009-12-21 2011-12-01 Colgate Palmolive Co Oral care compositions and methods
US8883473B2 (en) * 2011-06-29 2014-11-11 Janssen Pharmaceutica N.V. Methods of treatment using allosteric processing inhibitors for matrix metalloproteinases
RU2488587C1 (ru) * 2012-05-23 2013-07-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Казанский национальный исследовательский технологический университет" Анилид гидроксиметиланилинометилфосфиновой кислоты (амидофос) в качестве биостимулятора активного ила в процессе очистки сточных вод и способ его получения
CA3234750A1 (en) 2015-10-23 2017-04-27 Navitor Pharmaceuticals, Inc. Modulators of sestrin-gator2 interaction and uses thereof
US20190008828A1 (en) 2015-12-28 2019-01-10 The U.S.A., As Represented By The Secretary Department Of Health And Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
WO2017133517A1 (zh) * 2016-02-03 2017-08-10 四川海思科制药有限公司 一种磷酰胺衍生物及制备方法和用途
AU2017257185B9 (en) * 2016-04-29 2023-07-06 Ophirex, Inc. Phospholipase A2 inhibitors for immediate treatment of venom toxicity that causes hemolysis, cerebral edema, and acute kidney injury
CN106905183B (zh) * 2017-02-24 2018-07-31 三峡大学 一类含氨基的ɑ-酰氧基羰基酰胺类衍生物，制备方法及其应用
JP7179015B2 (ja) 2017-04-26 2022-11-28 ナビター ファーマシューティカルズ， インコーポレイテッド Ｓｅｓｔｒｉｎ－ＧＡＴＯＲ２相互座用のモジュレーターおよびその使用
US11345654B2 (en) 2018-10-24 2022-05-31 Navitor Pharmaceuticals, Inc. Polymorphic compounds and uses thereof
JP2022554276A (ja) 2019-11-01 2022-12-28 ナビター ファーマシューティカルズ， インコーポレイテッド Ｍｔｏｒｃ１モジュレーターを使用する処置方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601368D0 (en) * 1986-01-21 1986-02-26 Ici America Inc Hydroxamic acids
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8919251D0 (en) * 1989-08-24 1989-10-04 British Bio Technology Compounds
DE4011172A1 (de) * 1990-04-06 1991-10-10 Degussa Verbindungen zur bekaempfung von pflanzenkrankheiten
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
GB9107368D0 (en) * 1991-04-08 1991-05-22 Smithkline Beecham Plc Novel compounds
IL98681A (en) * 1991-06-30 1997-06-10 Yeda Rehovot And Dev Company L Pharmaceutical compositions comprising hydroxamate derivatives for iron removal from mammalian cells and from pathogenic organisms and some novel hydroxamate derivatives
DE4127842A1 (de) * 1991-08-22 1993-02-25 Rhone Poulenc Rorer Gmbh 5-((omega)-arylalky)-2-thienyl alkansaeuren, ihre salze und/oder ihre derivate
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
EP0634998B1 (en) * 1992-04-07 1997-03-19 British Biotech Pharmaceuticals Limited Hydroxamic acid based collagenase and cytokine inhibitors
EP0639982A1 (en) * 1992-05-01 1995-03-01 British Biotech Pharmaceuticals Limited Use of mmp inhibitors
AU666727B2 (en) * 1992-06-25 1996-02-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
ATE191468T1 (de) * 1994-06-22 2000-04-15 British Biotech Pharm Metalloproteinase inhibitoren

Also Published As

Publication number Publication date
DK0925303T3 (da) 2003-02-24
CN1228780A (zh) 1999-09-15
ID18145A (id) 1998-03-05
PE107698A1 (es) 1999-02-11
CA2264254C (en) 2003-03-11
NO990857L (no) 1999-04-28
BR9713182A (pt) 1999-11-03
NO990857D0 (no) 1999-02-23
AU732653B2 (en) 2001-04-26
DE69716619T2 (de) 2003-06-26
AR009357A1 (es) 2000-04-12
KR20000035925A (ko) 2000-06-26
PL331854A1 (en) 1999-08-16
TW518338B (en) 2003-01-21
US5830915A (en) 1998-11-03
CZ63699A3 (cs) 1999-07-14
DE69716619D1 (en) 2002-11-28
ATE226590T1 (de) 2002-11-15
IL128668A0 (en) 2000-01-31
WO1998008853A1 (en) 1998-03-05
IL128668A (en) 2002-02-10
TR199900399T2 (xx) 1999-06-21
ZA977700B (en) 1998-02-23
EP0925303B1 (en) 2002-10-23
EP0925303A1 (en) 1999-06-30
AU4153197A (en) 1998-03-19
CO4900033A1 (es) 2000-03-27
RU2170232C2 (ru) 2001-07-10
JP3539736B2 (ja) 2004-07-07
JP2000515167A (ja) 2000-11-14
CA2264254A1 (en) 1998-03-05
NZ334258A (en) 2000-11-24
SK25499A3 (en) 2000-03-13
HUP9903916A3 (en) 2001-06-28

Similar Documents

Publication Publication Date Title
HUP9903916A2 (hu) Foszfinsavamidok és ezeket tartalmazó gyógyszerkészítmények
HUP0000591A2 (hu) Fémproteáz inhibitor hatású piperazin-, morfolin- és tiomorfolin-származékok és alkalmazásuk gyógyszerkészítmények előállítására
DE60041973D1 (de) Substituierte piperidin-verbindungen als modulatoren der chemokine receptor aktivität
ES2160156T3 (es) Derivados de naftaleno como agonistas de la prostaglandina i2.
MY117896A (en) Quinazoline derivatives
HUP0201088A2 (hu) Új alfa-aminosav-szulfonil-vegyületek, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyászati készítmények
PL369078A1 (en) Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
HUP0002495A1 (hu) VLA-4 Által közvetített leukocita adhéziót gátló dipeptidszármazékok és rokon vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP9904694A2 (hu) Spiro-pirrolidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
TR200002971T2 (tr) İkameli pirolidin hidroksamat metaloproteaz inhibitörleri
HUP0002272A2 (hu) Piperazinszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0401598A2 (hu) Heterogyűrűs vegyületek a vizeletvezető rendszer rendellenességeinek kezelésében való használatra, és ezeket tartalmazó gyógyszerkészítmények
NO305174B1 (no) Heterocykliske forbindelser
HUP0202934A2 (hu) [(Aril-szulfonil)-amino]-szubsztituált hidroxámsav-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
PT916651E (pt) DERIVADOS DE áCIDO FENILALQUILCARBOXILICO
DE69707372D1 (de) Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne
YU64400A (sh) Aril fuzirana azapoliciklična jedinjenja
HUP0300235A2 (hu) Heterociklikus oldalláncot tartalmazó, N-szubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0303204A2 (hu) 1-Metilkarbapenem-származékok és ezeket tartalmazó gyógyszerkészítmények
HU9201033D0 (en) Tiazolidinone- and oxazolidinone derivatives, process for their production, and for the production of medical preparations containing them as active agents
HUP9904659A2 (hu) Aril-karbonsav- és tetrazolszármazékok, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények
ATE214064T1 (de) Indane-1-ol derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DE60031699D1 (de) Hydroxyacetamidobenzolsulfonamidderivate
TR200200977T2 (tr) Beta konumunda iki kere sübstitüe edilmiş metaloproteaz engelleyiciler
TR200003877T2 (tr) İnsan CD23 üretiminin ve TNF salınmasının ihhibitörleri olan hiydroxamic acid türevleri